Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014
| Autor: | Brima Kargbo, Yang Sun, Cheng-Yu Wang, Yi Hu, Yun-Song Chen, David Kargbo, Wei-Wei Liu, Ya-Bin Song, Jia-Fu Jiang, Yao-Ping Wang, Alex Kanu, Changqing Bai, Yuxi Cao, Jun Qian, Yu Sun, Foday Dafae, Jin-Song Mu, Ze-Yuan Liu, Hong-Quan Wang, Wei-Min Nie, Yong-Qiang Deng, Liu Wensen, Hong Wang, Liu Liu, George F. Gao, Yigang Tong, Wenkai Niu, Xiao-Guang Zhang, Hui-Jun Lu, Haoxiang Su, Fan Yang, Tao Yan |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Microbiology (medical) Adult Male medicine.medical_specialty Adolescent Kaplan-Meier Estimate Favipiravir medicine.disease_cause Antiviral Agents law.invention Sierra leone Sierra Leone 03 medical and health sciences Young Adult Randomized controlled trial law Internal medicine medicine Humans Survival rate Retrospective Studies Ebola virus business.industry Outbreak Hemorrhagic Fever Ebola Viral Load Ebolavirus Amides 030104 developmental biology Infectious Diseases Supportive psychotherapy Pyrazines Immunology Female business Viral load |
| Zdroj: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 63(10) |
| ISSN: | 1537-6591 |
| Popis: | Background During 2014-2015, an outbreak of Ebola virus disease (EVD) swept across parts of West Africa. No approved antiviral drugs are available for Ebola treatment currently. Methods A retrospective clinical case series was performed for EVD patients in Sierra Leone-China Friendship Hospital. Patients with confirmed EVD were sequentially enrolled and treated with either World Health Organization (WHO)-recommended supportive therapy (control group) from 10 to 30 October, or treated with WHO-recommended therapy plus favipiravir (T-705) from 1 to 10 November 2014. Survival and virological characteristics were observed for 85 patients in the control group and 39 in the T-705 treatment group. Results The overall survival rate in the T-705 treatment group was higher than that of the control group (56.4% [22/39] vs 35.3% [30/85]; P = .027). Among the 35 patients who finished all designed endpoint observations, the survival rate in the T-705 treatment group (64.8% [11/17]) was higher than that of the control group (27.8% [5/18]). Furthermore, the average survival time of the treatment group (46.9 ± 5.6 days) was longer than that of the control group (28.9 ± 4.7 days). Most symptoms of patients in the treatment group improved significantly. Additionally, 52.9% of patients who received T-705 had a >100-fold viral load reduction, compared with only 16.7% of patients in the control group. Conclusions Treatment of EVD with T-705 was associated with prolonged survival and markedly reduced viral load, which makes a compelling case for further randomized controlled trials of T-705 for treating EVD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|